Medical News

RSS

The Beryl Companies in Inc. 5000 list of the fastest-growing private companies

The Beryl Companies, the nation's leading provider of outsourced call center services to healthcare organizations, has achieved a growth rate of 41 percent in the last three years, earning it a place in the prestigious Inc. 5000 list of the fastest-growing private companies in the country for the third straight year.

19 Oct 2009

Lux Biosciences raises $50 million through Series B venture financing

Lux Biosciences, Inc., a privately held biotechnology company focused on the development and commercialization of therapies for serious ophthalmic diseases, today announced that the company has closed a $50 million Series B venture financing. Participants in the funding were current investors in Lux Biosciences, HBM Bioventures, Novo A/S, Prospect Venture Partners and SV Life Sciences (SVLS), as well as SVLS' publicly traded fund, International Biotechnology Trust plc.

19 Oct 2009

Sigma-Aldrich launches SAGEspeed, a program for developing human disease models in rodents

Sigma-Aldrich® (Nasdaq: SIAL) today announced the launch of SAGEspeed(TM), a program to develop human disease models in rodents using its proprietary novel CompoZr(TM) Zinc Finger Nuclease (ZFN) gene editing technology (http://www.compozrzfn.com).

19 Oct 2009

Anodyne Health Partners acquired by athenahealth

athenahealth, Inc., a leading provider of internet-based business services for physician practices, announced that it has completed the acquisition of Anodyne Health Partners, Inc. in an all-cash transaction that closed on Friday, October 16, 2009. This acquisition was publically announced on October 5, 2009.

19 Oct 2009

Yissum scientists invent new design of TeraHertz-ray

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., the technology transfer arm of the University, today announced that Professor L.D. Shvartsman and Professor B. Laikhtman, from the Racah Institute of Physics at the Hebrew University of Jerusalem, have invented a novel design of TeraHertz-ray, or T-ray, lasers.

19 Oct 2009

SequelMed Patient Portal launched by Sequel Systems

Sequel Systems, Inc., a dynamic, service-oriented healthcare technology company, today announced the launch and general availability of SequelMed Patient Portal™, a new, Web-based tool that improves and speeds up communication between physicians and patients, giving patients instant access to their personal health information, and allowing physicians and other healthcare providers more time to focus on delivering the best possible care. SequelMed Patient Portal is the latest addition to Sequel Systems’ suite of healthcare solutions, which includes an electronic health record (EHR), practice and document management software, and e-prescribing technology. More than 12,000 physicians in all 50 states and representing all major specialties currently use the company’s solutions.

19 Oct 2009

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Schering-Plough announced that data on boceprevir, an investigational hepatitis C virus (HCV) protease inhibitor, will be reported in an oral presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston, Oct. 30-Nov. 3.

19 Oct 2009

Sonomax Hearing Healthcare, Hearing Coach Africa sign five-year licensing agreement

Sonomax Hearing Healthcare Inc. is pleased to announce that it has signed a five year license agreement with Hearing Coach Africa (Pty). The agreement for V3 hearing protectors specifies quarterly commitments over five years, totaling a minimum of $1,000,000. The agreement is renewable for an additional 5 years if all contractual conditions and minimum quarterly commitments are met.

19 Oct 2009

Children's Hospital Boston's CRAFFT substance abuse diagnostic test helps identify high risk sexual behavior

Alcohol and drug use are known contributors to adolescents engaging in dangerous sexual activity; leading to substantial health risks such as unwanted pregnancies, sexually transmitted illnesses, drug overdoses and alcohol poisonings. Yet, research suggests that fewer than half of pediatricians report screening patients for substance use and at-risk sexual behavior.

19 Oct 2009

Ardea Biosciences reports results of RDEA594 Phase 2a study for hyperuricemia and gout

Ardea Biosciences, Inc. announced additional positive results from the completed first cohort of an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout.

19 Oct 2009

New series of single output power supplies from ICC

International Components Corporation (ICC), an established global leader in designing and manufacturing portable rechargeable systems, today launched a new series of high-efficiency AC-DC open-frame, single output power supplies marketed under the Elpac Power Systems(TM) brand name.

19 Oct 2009

Vaccinations and preventative hygiene routines can help protect families from H1N1

According to the Centers for Disease Control and Prevention (CDC), 37 states in the U.S. now report widespread influenza activity - and nearly all influenza cases reported to the health authority are 2009 H1N1, also known as swine flu. However, with the release of a 2009 H1N1 vaccine this week, parents have a new preventative tool to help keep their families safe from illness.

19 Oct 2009

Hansen Medical announces its plan to restate its previous financial results

Hansen Medical, Inc. today announced that it plans to restate its financial statements for the year ended December 31, 2008 and for the quarters ended March 31, 2008, June 30, 2008, September 30, 2008, March 31, 2009 and June 30, 2009 in order to correct certain errors, some of which arose from potential irregularities occurring outside of the accounting department, regarding the timing of revenue recognition on the sale of some of its Sensei® Robotic Catheter Systems.

19 Oct 2009

FDA approves Quotient Biodiagnostics' BLA for transfusion diagnostic monoclonal antibodies

Quotient Biodiagnostics, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved its biologics license application (BLA) for the first 15 monoclonal antibodies in its proprietary line of transfusion diagnostics. These products are for use by blood donor centers, reference laboratories, and hospitals to type and screen blood.

19 Oct 2009

GenoLogics and CLC bio to provide end-to-end informatics solution for workflow management

GenoLogics and CLC bio today announced they will provide an end-to-end informatics and analysis solution, optimized for Next Generation Sequencing research that addresses both lab and data management and data analysis all within one integrated system.

19 Oct 2009

Phase 3 clinical trial of macimorelin (AEZS-130) to be completed by AEterna Zentaris

AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that it has initiated activities intended to complete the clinical development of the growth hormone secretagogue (GHS) / ghrelin agonist compound macimorelin (AEZS-130) which could be the first oral diagnostic test approved for growth hormone deficiency (GHD). Macimorelin is the International Non-proprietary Name (INN) designated for the compound by the World Health Organization (WHO).

19 Oct 2009

XenoPort commences Phase 2b arbaclofen placarbil clinical trial for treating gastroesophageal reflux disease

XenoPort, Inc. announced today that it has initiated a Phase 2b clinical trial of arbaclofen placarbil (AP), also known as XP19986, in patients with gastroesophageal reflux disease (GERD) who remain symptomatic despite treatment with a proton pump inhibitor (PPI). The trial is a multi-center, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of AP as adjunctive therapy to PPIs.

19 Oct 2009

Metabolic master switch sets the biological clock in body tissues

Our body's activity levels fall and rise to the beat of our internal drums-the 24-hour cycles that govern fundamental physiological functions, from sleeping and feeding patterns to the energy available to our cells. Whereas the master clock in the brain is set by light, the pacemakers in peripheral organs are set by food availability. The underlying molecular mechanism was unknown.

19 Oct 2009

Sonosite resolves all pending patent litigation with General Electric

SonoSite, Inc., the world leader and specialist in hand-carried ultrasound for the point-of-care, announced today that the company has resolved all pending patent litigation with General Electric Company (GE).

19 Oct 2009

Campaign to educate men and women about fibromyalgia

Women and men have opposing views on many topics, and it turns out that they also have different takes on chronic pain.

19 Oct 2009

Medical News

The Beryl Companies in Inc. 5000 list of the fastest-growing private companies

Lux Biosciences raises $50 million through Series B venture financing

Sigma-Aldrich launches SAGEspeed, a program for developing human disease models in rodents

Anodyne Health Partners acquired by athenahealth

Yissum scientists invent new design of TeraHertz-ray

SequelMed Patient Portal launched by Sequel Systems

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Sonomax Hearing Healthcare, Hearing Coach Africa sign five-year licensing agreement

Children's Hospital Boston's CRAFFT substance abuse diagnostic test helps identify high risk sexual behavior

Ardea Biosciences reports results of RDEA594 Phase 2a study for hyperuricemia and gout

New series of single output power supplies from ICC

Vaccinations and preventative hygiene routines can help protect families from H1N1

Hansen Medical announces its plan to restate its previous financial results

FDA approves Quotient Biodiagnostics' BLA for transfusion diagnostic monoclonal antibodies

GenoLogics and CLC bio to provide end-to-end informatics solution for workflow management

Phase 3 clinical trial of macimorelin (AEZS-130) to be completed by AEterna Zentaris

XenoPort commences Phase 2b arbaclofen placarbil clinical trial for treating gastroesophageal reflux disease

Metabolic master switch sets the biological clock in body tissues

Sonosite resolves all pending patent litigation with General Electric

Campaign to educate men and women about fibromyalgia

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Latest News